Objective:To explore the clinical efficacy and safety of magnesium valproate sustained-release tablets combined with quetiapine in patients with depressive phase of bipolar affective disorder.Methods:A total of 80 patients with bipolar disorder admitted to hospital were selected and divided into a control group of 40 cases and a study group of 40 cases according to their order of visit.The control group received only magnesium valproate sustained-release tablets,while the study group received both quetiapine and magnesium valproate sustained-release tablets,both for a duration of 6 weeks.Adverse reactions,clinical efficacy,and differences in scale scores before and after treatment were observed in both groups.Changes in PRL,TSH,FT4,and FT3 levels before and after treatment were analyzed in both groups.Results:The total effective rate in the study group was higher than the control group's(P＜0.05).There was no significant difference in PRL,TSH,FT4,and FT3 levels between the two groups before treatment(P＞0.05).After treatment,both groups showed an increase in PRL compared to before treatment(P＜0.05),and TSH levels increased while FT4 and FT3 levels decreased in both groups(P＜0.05).There was no significant difference in TSH,FT4,and FT3 levels between the two groups after treatment(P＞0.05).Conclusion:Magnesium valproate sustained-release tablets combined with quetiapine significantly improve the clinical efficacy of treating bipolar affective disorder with fewer adverse effects.Additionally,the combined treatment has minimal impact on thyroid function compared to single-drug therapy.
bipolar affective disordermagnesium valproatequetiapinethyroid function
NETL
NSTL
万方数据
